Resolution of controversies in drug/receptor interactions by protein structure. Limitations and pharmacological solutions

Neuropharmacology

Volumn 60, Issue 1, 2011, Pages 3-6

  Spedding, Michael ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Drug interaction; GPCR

Indexed keywords

1 [2 (4 FLUOROBENZAMIDO)ETHYL] 4 (7 METHOXY 1 NAPHTHYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BUSPIRONE; FLUVOXAMINE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RS 30199; RS 64459; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; LIGAND BINDING; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

DRUG DESIGN; DRUG INTERACTIONS; LIGANDS; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149500062     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.08.002     Document Type: Review

References (28)

1. Bokoch M.P., Zou Y., Rasmussen S.G., Liu C.W., Nygaard R., Rosenbaum D.M., Fung J.J., Choi H.J., Thian F.S., Kobilka T.S., Puglisi J.D., Weis W.I., Pardo L., Prosser R.S., Mueller L., Kobilka B.K. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010, 463:108-112.
2. Chandra V., Huang P., Hamuro Y., Raghuram S., Wang Y., Burris T.P., Rastinejad F. Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature 2008, 456:350-356.
3. Colquhoun D. The relation between classical and cooperative models for drug action. Drug Receptors 1973, 149-182. Macmillan Press, London. H.P. Rang (Ed.).
4. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol. 1998, 125:924-947.
5. Germain P., Staels B., Dacquet C., Spedding M., Laudet V. Overview of nomenclature of nuclear receptors. Pharm. Rev. 2006, 58:685-704.
6. Harmar A.J., Hills R.A., Rosser E.M., Jones M., Buneman O.P., Dunbar D.R., Greenhill S.D., Hale V.A., Sharman J.L., Bonner T.I., Catterall W.A., Davenport A.P., Delagrange P., Dollery C.T., Foord S.M., Gutman G.A., Laudet V., Neubig R.R., Ohlstein E.H., Olsen R.W., Peters J., Pin J.P., Ruffolo R.R., Searls D.B., Wright M.W., Spedding M. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res. 2009, 37(Database issue):D680-D685.
7. Hubbard R. Structure-based drug discovery and protein targets in the CNS. Neuropharmacology 2011, 60:7-23.
8. Jacoby E., Raimbaud E., Ollivier S., Michel A., Spedding M. The molecular architecture of ligands and receptor mutation experiments reveal a three binding site hypothesis for the interaction of ligands with monoamine G-protein coupled receptors: implications for combinatorial ligand design. QSAR 1999, 18:561-572.
9. Kelly E., Bailey C.P., Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br. J. Pharmacol. 2008, 153(Suppl. 1):S379-S388.
10. Lape R., Colquhoun D., Sivilotti L.G. On the nature of partial agonism in the nicotinic receptor superfamily. Nature 2008, 454:722-727.
11. 1A receptors. Neuropharmacology 2000, 40:334-344.
12. Muniz-Medina V.M., Jones S., Maglich J.M., Galardi C., Hollingsworth R.E., Kazmierski W.M., Ferris R.G., Edelstein M.P., Chiswell K.E., Kenakin T.P. The relative activity of " function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?. Mol. Pharmacol. 2009, 75:490-501.
13. 1A receptors by the inverse agonist spiperone but not the neutral antagonist WAY 100,635. Br. J. Pharmacol. 1997, 120:737-739.
14. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., Schacht A.L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214.
15. Pin J.P., Neubig R., Bouvier M., Devi L., Filizola M., Javitch J.A., Lohse M.J., Milligan G., Palczewski K., Parmentier M., Spedding M. International Union of Basic and Clinical Pharmacology. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol. Rev. 2007, 59:5-13.
16. Pøhlsgaard J., Frydenvang K., Madsen U., Kastrup J.S. Lessons from more than 80 structures of the GluA2 ligand-binding domain in complex with agonists, antagonists and allosteric modulators. Neuropharmacology 2011, 60:135-150.
17. Robertson N., Jazayeri A., Errey J., Baig A., Hurrell E., Zhukov A., Langmead C.J., Weir M., Marshall F. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in Drug Discovery. Neuropharmacology 2011, 60:36-44.
18. Rondard P., Goudet C., Kniazeff J., Pin J.P., Prézeau L. Complexity in activation mechanism opens new possibilities to modulate class C G protein coupled receptors. Neuropharmacology 2011, 60:82-92.
19. Rosenbaum D.M., Rasmussen S.G., Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature 2009, 459:356-363.
20. Schmid C.L., Raehal K.M., Bohn L.M. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc. Natl. Acad. Sci. U S A 2008, 105:1079-1084.
21. Sobolevsky A.I., Rosconi M.P., Gouaux E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 2009, 462:745-756.
22. Spedding M., Dacquet C. Transduction is a major factor influencing receptor characterisation. Ann. NY Acad. Sci. 1996, 812:29-40.
23. 1A receptors: modulation of sexual activity in the male rat. Neuropharmacology 1998, 37:769-780.
24. Talbot J.N., Jutkiewicz E.M., Graves S.M., Clemans C.F., Nicol M.R., Mortensen R.M., Huang X., Neubig R.R., Traynor J.R. RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects. Proc. Natl. Acad. Sci. U S A 2010, 107:11086-11091.
25. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B.K., Weinstein H., Javitch J.A., Roth B.L., Christopoulos A., Sexton P., Miller K., Spedding M., Mailman R.B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharm. Exp. Ther. 2007, 320:1-13.
26. Valant C., Sexton P.M., Christopoulos A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol. Interv. 2009, 9:125-135.
27. Violin J.D., Lefkowitz R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 2007, 28:416-422.
28. Woo A.Y., Wang T.B., Zeng X., Zhu W., Abernethy D.R., Wainer I.W., Xiao R.P. Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol. Pharmacol. 2009, 75:158-165.